First human test: can a new drug called ADB116 be given safely?
NCT ID NCT07729839
First seen Jul 28, 2026 · Last updated Aug 06, 2026 · Updated 3 times
Summary
This early-stage trial is testing whether a single intravenous dose of an experimental drug called ADB116 is safe and tolerable in healthy Chinese adults aged 18 to 45. Researchers will monitor participants for side effects and measure how the drug moves through the body. The study does not aim to treat any disease; it is a first step to gather essential safety data before any future trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called ADB116 given as a single injection into a vein
- What could go wrong
- This is an early Phase I trial with only 26 healthy participants, so it is not designed to test effectiveness. The main goal is safety, and unexpected side effects may occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NanFang Hospital of Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510515, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill ACC017 be safely dosed? a trial seeks answers
- Can a fingerprint scan replace traditional drug tests?
- Gut feeling: could probiotics soothe the mind?
- A window to the brain? eye signals may track dopamine
- Can a common heartburn pill change how a cancer drug works?
- Breathing exercises may rewire tongue control — a pilot study puts the idea to the test